Vontobel Holding Ltd. Invests $51,000 in Perspective Therapeutics, Inc. (NYSE:CATX)

Vontobel Holding Ltd. purchased a new position in shares of Perspective Therapeutics, Inc. (NYSE:CATX) in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund purchased 16,000 shares of the company’s stock, valued at approximately $51,000.

Other institutional investors and hedge funds also recently modified their holdings of the company. The Manufacturers Life Insurance Company increased its stake in Perspective Therapeutics by 8.9% in the third quarter. The Manufacturers Life Insurance Company now owns 20,514 shares of the company’s stock valued at $274,000 after purchasing an additional 1,672 shares during the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its position in Perspective Therapeutics by 5.8% during the 3rd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 58,678 shares of the company’s stock worth $783,000 after purchasing an additional 3,211 shares during the period. US Bancorp DE grew its stake in shares of Perspective Therapeutics by 142.7% in the third quarter. US Bancorp DE now owns 6,576 shares of the company’s stock valued at $88,000 after buying an additional 3,866 shares in the last quarter. JPMorgan Chase & Co. boosted its stake in shares of Perspective Therapeutics by 24.1% in the third quarter. JPMorgan Chase & Co. now owns 24,912 shares of the company’s stock valued at $333,000 after purchasing an additional 4,844 shares during the period. Finally, Trueblood Wealth Management LLC increased its position in shares of Perspective Therapeutics by 37.0% during the fourth quarter. Trueblood Wealth Management LLC now owns 22,236 shares of the company’s stock worth $71,000 after acquiring an additional 6,000 shares during the last quarter. Hedge funds and other institutional investors own 54.66% of the company’s stock.

Perspective Therapeutics Stock Down 1.9 %

Shares of NYSE CATX opened at $2.79 on Friday. Perspective Therapeutics, Inc. has a 12 month low of $2.70 and a 12 month high of $19.05. The business’s 50 day moving average is $3.31 and its two-hundred day moving average is $8.47.

Insider Transactions at Perspective Therapeutics

In related news, Director Heidi Henson acquired 25,975 shares of the business’s stock in a transaction dated Wednesday, December 4th. The stock was acquired at an average price of $3.85 per share, with a total value of $100,003.75. Following the completion of the transaction, the director now owns 25,975 shares of the company’s stock, valued at approximately $100,003.75. This represents a ∞ increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CEO Johan M. Spoor bought 8,000 shares of the firm’s stock in a transaction that occurred on Wednesday, December 4th. The shares were purchased at an average cost of $3.77 per share, for a total transaction of $30,160.00. Following the completion of the transaction, the chief executive officer now owns 36,257 shares of the company’s stock, valued at $136,688.89. This represents a 28.31 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Over the last quarter, insiders have purchased 67,570 shares of company stock worth $256,789. Insiders own 3.52% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research analysts have commented on CATX shares. Royal Bank of Canada reaffirmed an “outperform” rating and set a $16.00 target price on shares of Perspective Therapeutics in a report on Tuesday, January 14th. Cantor Fitzgerald upgraded shares of Perspective Therapeutics to a “strong-buy” rating in a research report on Wednesday, February 5th. Oppenheimer lowered their target price on Perspective Therapeutics from $22.00 to $16.00 and set an “outperform” rating on the stock in a report on Friday, November 22nd. Wedbush reiterated an “outperform” rating and issued a $11.00 price target on shares of Perspective Therapeutics in a research report on Friday, January 24th. Finally, Bank of America cut shares of Perspective Therapeutics from a “buy” rating to a “neutral” rating and lowered their price objective for the stock from $24.00 to $5.00 in a research report on Monday, November 25th. One research analyst has rated the stock with a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, Perspective Therapeutics has a consensus rating of “Buy” and a consensus target price of $15.14.

About Perspective Therapeutics

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.